UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for UroGen Pharma in a report released on Monday, April 28th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.47) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for UroGen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma's Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.24 EPS and Q4 2026 earnings at $0.54 EPS.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million.
A number of other brokerages also recently commented on URGN. Scotiabank began coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 target price for the company. Guggenheim reissued a "buy" rating on shares of UroGen Pharma in a research report on Tuesday, April 29th. The Goldman Sachs Group reduced their price objective on UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Monday, April 28th. Finally, LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, UroGen Pharma presently has a consensus rating of "Buy" and an average price target of $32.86.
Get Our Latest Report on UroGen Pharma
UroGen Pharma Stock Down 3.2 %
Shares of URGN traded down $0.37 during trading hours on Wednesday, hitting $11.14. The company had a trading volume of 193,702 shares, compared to its average volume of 534,858. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a market capitalization of $513.63 million, a PE ratio of -3.54 and a beta of 0.66. UroGen Pharma has a one year low of $8.94 and a one year high of $20.70. The company's fifty day moving average price is $10.54 and its two-hundred day moving average price is $11.04.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of URGN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in UroGen Pharma by 4.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock worth $231,000 after purchasing an additional 969 shares during the period. Rhumbline Advisers grew its stake in UroGen Pharma by 2.8% in the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock valued at $546,000 after acquiring an additional 1,402 shares during the period. MetLife Investment Management LLC increased its holdings in UroGen Pharma by 13.6% in the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock worth $242,000 after acquiring an additional 2,727 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in UroGen Pharma by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock valued at $996,000 after purchasing an additional 3,024 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of UroGen Pharma by 24.6% in the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock valued at $211,000 after purchasing an additional 3,920 shares during the period. Institutional investors and hedge funds own 91.29% of the company's stock.
UroGen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Stories
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
